HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.

Abstract
Pfizer Inc is developing tremelimumab, a fully human monoclonal IgG2 antibody against cytotoxic T-lymphocyte-associated antigen, for the potential intravenous treatment of cancer. Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer.
AuthorsAhmad A Tarhini, John M Kirkwood
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 9 Issue 5 Pg. 505-14 (Oct 2007) ISSN: 1464-8431 [Print] England
PMID17932815 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Cancer Vaccines
  • Immunoglobulin G
  • tremelimumab
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD (immunology)
  • Antigens, Differentiation (immunology)
  • CTLA-4 Antigen
  • Cancer Vaccines (therapeutic use)
  • Drug Evaluation, Preclinical
  • Humans
  • Immunoglobulin G (therapeutic use)
  • Melanoma (immunology, secondary, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: